Current Value
$8.241 Year Return
Current Value
$8.241 Year Return
Double maintains 1 strategies that include COGT - Cogent Biosciences, Inc.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CME | -12.60% | $90.13B | +18.52% | 4.18% |
PRT | -12.50% | $52.92M | -1.81% | 9.86% |
PAYO | -12.14% | $3.74B | +92.29% | 0.00% |
INGR | -10.51% | $8.36B | +11.61% | 2.47% |
LITB | -10.04% | $18.75M | -83.65% | 0.00% |
SEG | -9.91% | $337.07M | +3.01% | 0.00% |
RDDT | -9.17% | $35.98B | +502.79% | 0.00% |
STVN | -9.02% | $5.20B | -40.57% | 0.30% |
SMC | -8.96% | $481.43M | +169.27% | 0.00% |
PRPO | -7.52% | $10.94M | +11.01% | 0.00% |
PULM | -7.39% | $27.36M | +307.07% | 0.00% |
ALAB | -7.04% | $13.99B | +144.97% | 0.00% |
LICY | -6.95% | $29.96M | -74.75% | 0.00% |
STG | -6.81% | $35.60M | -18.31% | 0.00% |
NNE | -6.77% | $1.11B | +743.25% | 0.00% |
TAC | -6.47% | $3.11B | +49.50% | 1.69% |
TEM | -6.45% | $13.19B | 0.00% | 0.00% |
FAT | -5.93% | $68.94M | -22.97% | 14.40% |
UVE | -5.74% | $574.78M | +17.46% | 3.17% |
KC | -5.68% | $4.40B | +528.62% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CYD | 0.03% | $458.02M | +31.11% | 3.35% |
FWRD | -0.06% | $877.32M | -26.15% | 0.00% |
TH | -0.07% | $939.94M | +0.53% | 0.00% |
MO | 0.10% | $90.88B | +33.48% | 7.48% |
CMG | -0.13% | $78.79B | +11.02% | 0.00% |
XGN | 0.14% | $75.31M | +97.69% | 0.00% |
AWH | 0.16% | $4.95M | -94.08% | 0.00% |
EZPW | 0.16% | $790.02M | +32.29% | 0.00% |
MOMO | -0.17% | $1.03B | +37.93% | 0.00% |
DIS | 0.17% | $198.12B | -2.54% | 0.87% |
LNG | 0.19% | $47.11B | +32.10% | 0.88% |
HEES | 0.26% | $3.20B | +55.33% | 1.25% |
TAL | -0.30% | $6.78B | +1.02% | 0.00% |
QXO | -0.35% | $5.42B | -86.95% | 0.00% |
NOC | -0.37% | $65.87B | +1.12% | 1.79% |
BACK | 0.39% | $1.24M | -67.57% | 0.00% |
CYCN | -0.40% | $8.21M | +4.81% | 0.00% |
CMBT | -0.41% | $2.04B | -40.78% | 10.09% |
TKC | -0.46% | $6.54B | +37.43% | 2.77% |
KDP | 0.49% | $43.23B | +2.51% | 2.77% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
WEAT | 0.13% | $125.72M | 0.28% |
SGOV | 0.32% | $33.82B | 0.09% |
GSG | 0.32% | $1.08B | 0.75% |
FMF | 0.81% | $156.25M | 0.95% |
USCI | -1.06% | $215.20M | 1.07% |
CLOZ | -1.10% | $926.79M | 0.5% |
SPYT | -1.11% | $105.75M | 0.94% |
FLRN | -1.11% | $2.62B | 0.15% |
SHYD | 1.30% | $319.45M | 0.35% |
PDBC | 1.48% | $4.78B | 0.59% |
IBMO | -1.55% | $509.23M | 0.18% |
DBC | 1.59% | $1.38B | 0.87% |
KRBN | -1.75% | $192.93M | 0.85% |
GBIL | 1.87% | $5.76B | 0.12% |
TAXF | 1.87% | $520.32M | 0.29% |
COMT | -2.31% | $745.89M | 0.48% |
CORN | 2.37% | $65.57M | 0.2% |
XBIL | 2.40% | $664.34M | 0.15% |
DBMF | 2.60% | $1.41B | 0.85% |
JUCY | 2.64% | $310.25M | 0.6% |
Finnhub
WALTHAM, Mass. and BOULDER, Colo., Jan. 30, 2025 -- Cogent Biosciences, Inc. , a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced...
SeekingAlpha
Despite a 15% drop in the SPDR S&P Biotech ETF, insider buying presents opportunities. Read why these small and mid-cap biotech stocks are worth a closer look.
SeekingAlpha
Bezuclastinib's upcoming data in July 2025 could be a game-changer for COGT, offering a lucrative investment opportunity. See why COGT stock is buy rated.
Finnhub
• Plan to report top-line results from registration-directed SUMMIT trial in NonAdvSM patients in July 2025 • Plan to report top-line results from pivotal PEAK Phase 3 trial in...
Yahoo
WALTHAM, Mass. and BOULDER, Colo., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 7:30 a.m. PT/10:30 a.m. ET. A live webcast will be available on the Investors & Media page of Cogen
Yahoo
56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50% reduction in TSS 89% of patients had >50% decrease in serum tryptase by four weeks of treatment and 95% of patients with elevated baseline tryptase achieved serum tryptase levels <20 ng/ml by week 24 SUMMIT Part 2 enrollment completed early; surpassing original enrollment target with 179 patients enrolled, top-line results now expected in July 2025 Cogent to host investor webcast today, Mo
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -18.91% | $277.56M | 1.43% |
VIXY | -16.31% | $195.31M | 0.85% |
KMLM | -15.58% | $327.00M | 0.9% |
AGZD | -14.49% | $135.16M | 0.23% |
TAIL | -14.39% | $62.82M | 0.59% |
USDU | -12.82% | $282.00M | 0.5% |
UUP | -12.63% | $389.72M | 0.77% |
DBA | -7.44% | $897.78M | 0.93% |
XHLF | -7.41% | $1.07B | 0.03% |
USFR | -6.49% | $17.58B | 0.15% |
USL | -5.93% | $49.89M | 0.85% |
CTA | -5.64% | $681.78M | 0.76% |
DBO | -5.52% | $191.98M | 0.77% |
TPMN | -5.22% | $34.10M | 0.65% |
USO | -4.80% | $1.12B | 0.6% |
BNO | -4.70% | $94.01M | 1% |
DBE | -4.70% | $56.04M | 0.77% |
FLTR | -4.68% | $2.14B | 0.14% |
OILK | -4.20% | $73.97M | 0.69% |
TFLO | -3.81% | $6.53B | 0.15% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 49.80% | $5.92B | 0.35% |
GNOM | 46.18% | $65.99M | 0.5% |
IBB | 45.78% | $6.33B | 0.45% |
PTH | 44.14% | $125.48M | 0.6% |
PBE | 43.94% | $245.59M | 0.58% |
XPH | 42.88% | $164.02M | 0.35% |
ARKG | 41.72% | $1.19B | 0.75% |
KJUL | 40.67% | $155.12M | 0.79% |
FBT | 40.27% | $1.15B | 0.56% |
BBH | 39.07% | $386.11M | 0.35% |
IWC | 38.63% | $956.01M | 0.6% |
KAPR | 38.62% | $162.71M | 0.79% |
HYGV | 38.40% | $1.51B | 0.37% |
IWO | 38.09% | $12.47B | 0.24% |
NUSC | 38.03% | $1.26B | 0.31% |
USHY | 37.93% | $18.55B | 0.08% |
IWM | 37.84% | $72.71B | 0.19% |
VTWO | 37.82% | $11.72B | 0.07% |
PINK | 37.65% | $142.29M | 0.5% |
JNK | 37.39% | $8.02B | 0.4% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LAW | 40.14% | $328.90M | -33.37% | 0.00% |
CIGI | 39.66% | $6.67B | +2.56% | 0.23% |
FATE | 39.34% | $144.65M | -82.06% | 0.00% |
NTLA | 38.34% | $981.82M | -66.14% | 0.00% |
ARWR | 37.70% | $2.41B | -35.37% | 0.00% |
IDYA | 36.92% | $1.79B | -55.30% | 0.00% |
XNCR | 35.81% | $1.14B | -23.52% | 0.00% |
TKR | 35.31% | $5.83B | +2.04% | 1.62% |
MQ | 35.03% | $1.82B | -44.39% | 0.00% |
REGN | 34.34% | $73.71B | -29.38% | 0.00% |
HZO | 34.01% | $652.61M | -10.72% | 0.00% |
TEL | 33.95% | $45.71B | +7.02% | 1.63% |
CRNX | 33.80% | $3.27B | -4.50% | 0.00% |
LFUS | 33.59% | $6.14B | +0.80% | 1.09% |
RCUS | 33.52% | $1.16B | -22.61% | 0.00% |
ALLO | 33.39% | $295.64M | -71.57% | 0.00% |
SCL | 33.37% | $1.40B | -33.22% | 2.40% |
FOXF | 33.37% | $1.07B | -62.37% | 0.00% |
BCRX | 33.35% | $1.83B | +56.38% | 0.00% |
RCKT | 33.14% | $1.08B | -66.84% | 0.00% |